361558
GSK-3 Inhibitor XV - Calbiochem
The GSK-3 Inhibitor XV controls the biological activity of GSK-3. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
동의어(들):
GSK-3 Inhibitor XV - Calbiochem
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C25H14BrN3O6Ru
Molecular Weight:
633.37
UNSPSC 코드:
12352200
Quality Level
분석
≥98% (HPLC)
형태
solid
제조업체/상표
Calbiochem®
저장 조건
OK to freeze
protect from light
색상
purple
solubility
DMSO: 6 mg/mL
배송 상태
wet ice
저장 온도
−20°C
일반 설명
The racemic mixture of a cell-permeable pyridocarbazolo-cyclopentadienyl Ruthenium complex that acts as a reversible, ATP-competitive, and highly potent inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively) with ∼5-fold selectivity over PIM-1 kinase (IC50 = 3 nM). Studies using isolated enantiomers have shown that the (R)-enantiomer is GSK-3-selective (IC50 = 0.35, 0.55, and 35 nM for GSK-3α GSK-3β, and Pim-1, respectively) and interferes with normal zebrafish embryo development (1 µM), while the (S)-enantiomer is Pim-1-selective (IC50 = 80, 90, and 3 nM for GSK-3α GSK-3β, and Pim-1, respectively) and exhibits no effect in embryo development at the same dosage.
생화학적/생리학적 작용
Cell permeable: yes
Product competes with ATP.
Reversible: yes
Target IC50: 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively
포장
Packaged under inert gas
경고
Toxicity: Standard Handling (A)
재구성
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
기타 정보
Atilla-Gokcumen, G.E., et al. 2006. ChemBioChem7, 1443.
법적 정보
Sold for research purposes only, pursuant to an agreement with University of Pennsylvania.Sold under license of U.S. Patent 7,488,817.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Rikke H Kofoed et al.
Neurobiology of disease, 136, 104720-104720 (2019-12-28)
Parkinson's disease (PD) is a currently incurable disease and the number of patients is expected to increase due to the extended human lifespan. α-Synuclein is a pathological hallmark of PD and variations and triplications of the gene encoding α-synuclein are
G Ekin Atilla-Gokcumen et al.
Chembiochem : a European journal of chemical biology, 7(9), 1443-1450 (2006-07-22)
A chiral second-generation organoruthenium half-sandwich compound is disclosed that shows a remarkable selectivity and cellular potency for the inhibition of glycogen synthase kinase 3 (GSK-3). The selectivity was evaluated against a panel of 57 protein kinases, in which no other
Xuzhe Zhang et al.
Molecular biology and evolution, 37(2), 507-523 (2019-10-22)
Evolution of highly invasive placentation in the stem lineage of eutherians and subsequent extension of pregnancy set eutherians apart from other mammals, that is, marsupials with short-lived placentas, and oviparous monotremes. Recent studies suggest that eutherian implantation evolved from marsupial
Lasse Reimer et al.
Brain pathology (Zurich, Switzerland), 31(1), 103-119 (2020-07-28)
Deposition of extensively hyperphosphorylated tau in specific brain cells is a clear pathological hallmark in Alzheimer's disease and a number of other neurodegenerative disorders, collectively termed the tauopathies. Furthermore, hyperphosphorylation of tau prevents it from fulfilling its physiological role as
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.